Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Department of VIP Region, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
Sci Rep. 2019 Dec 2;9(1):18122. doi: 10.1038/s41598-019-54731-9.
B7-H6, a member of the B7 family molecules, participates in the clearance of tumor cells by binding to NKp30 on NK cells. B7-H6 expression level in esophageal squamous cell carcinoma (ESCC) and the clinical value remain unknown. The goal of this study was to determine the expression of B7-H6 in ESCC and further explore its clinical significance. We retrospectively collected the clinical data of 145 patients diagnosed with ESCC between January 2007 and December 2008. The expression of B7-H6 of the pathological tissue samples was detected by immunohistochemistry. The chi-square (χ) test was used to analyse the relationships of B7-H6 and clinicopathological characteristics. Survival and hazard functions were estimated using the Kaplan-Meier method, and survival between groups was compared using the two-sided log-rank test. The Cox proportional hazards regression model was used to adjust for the risk factors related to overall survival (OS). 133/145 (91.72%) of the ESCC tissue samples exhibited B7-H6 expression. The expression level of B7-H6 was correlated with T stage (P = 0.036) and lymphatic metastasis status (P = 0.044). High B7-H6 expression (P = 0.003) was associated with a significantly worse OS than low B7-H6 expression. Multivariate Cox proportional hazards regression analysis demonstrated that tumour size (P = 0.021), B7-H6 expression (P = 0.025) and lymphatic metastasis status (P = 0.049) were independent prognostic factors of OS for ESCC. Collectively, our findings suggest that B7-H6 is widely expressed in ESCC samples. And B7-H6 may represent a predictor of poor prognosis for ESCC.
B7-H6 是 B7 家族分子的一员，通过与 NK 细胞上的 NKp30 结合参与肿瘤细胞的清除。B7-H6 在食管鳞状细胞癌（ESCC）中的表达水平及其临床价值尚不清楚。本研究旨在检测 ESCC 中 B7-H6 的表达，并进一步探讨其临床意义。我们回顾性收集了 2007 年 1 月至 2008 年 12 月期间诊断为 ESCC 的 145 例患者的临床资料。采用免疫组织化学法检测病理组织样本中 B7-H6 的表达。采用卡方（χ）检验分析 B7-H6 与临床病理特征的关系。采用 Kaplan-Meier 法估计生存和危险函数，并用双侧对数秩检验比较组间生存。采用 Cox 比例风险回归模型调整与总生存期（OS）相关的风险因素。145 例 ESCC 组织标本中有 133 例（91.72%）显示 B7-H6 表达。B7-H6 的表达水平与 T 分期（P=0.036）和淋巴转移状态（P=0.044）相关。高 B7-H6 表达（P=0.003）与 OS 明显较差相关。多因素 Cox 比例风险回归分析显示肿瘤大小（P=0.021）、B7-H6 表达（P=0.025）和淋巴转移状态（P=0.049）是 ESCC OS 的独立预后因素。综上，我们的研究结果表明 B7-H6 在 ESCC 样本中广泛表达。B7-H6 可能是 ESCC 预后不良的预测指标。
